Skip to main content
OpenTrials

Clinical trial condition

Chronic Lymphocytic Leukemia

Explore clinical trials studying Chronic Lymphocytic Leukemia. Study availability and eligibility vary by location and protocol.

528 public trials 91 recruiting studies
Refine in advanced search Browse all conditions

Chronic Lymphocytic Leukemia trial results

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Site Reference ID/Investigator #047 Duarte, California, United States
  • Site Reference ID/Investigator #408 La Jolla, California, United States
  • Site Reference ID/Investigator #720 Santa Rosa, California, United States
  • Site Reference ID/Investigator #038 Stanford, California, United States
View all 108 locations
View Trial Details
Completed

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

NCT01399840

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Chronic Disease, +24 more
Locations
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
  • University of Wisconsin Madison, Wisconsin, United States
  • University College London London, United Kingdom
View Trial Details
Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01369849

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +16 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Siouxland Regional Cancer Center Sioux City, Iowa, United States
  • Mercy Medical Center-Sioux City Sioux City, Iowa, United States
  • Saint Luke's Regional Medical Center Sioux City, Iowa, United States
View all 44 locations
View Trial Details
Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

NCT01500083

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • CA015 Calgary, Alberta, Canada
  • CA014 Edmonton, Alberta, Canada
  • CA016 Kelowna, British Columbia, Canada
  • CA011 Vancouver, British Columbia, Canada
View all 16 locations
View Trial Details
Completed

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

NCT00090051

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Uab Comprehensive Cancer Center Birmingham, Alabama, United States
  • Pacific Coast Hematology/Oncology Medical Group Fountain Valley, California, United States
  • California Cancer Center Woodward Park; Community Medical Centers Fresno, California, United States
  • Rush-Presbyterian St. Luke'S Medical Center Chicago, Illinois, United States
View all 106 locations
View Trial Details
Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

NCT00281983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +22 more
Locations
  • Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada
  • Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin Berlin, Germany
  • Universitaetsklinikum Essen Essen, Germany
  • Universitaetsklinikum Goettingen Göttingen, Germany
View all 13 locations
View Trial Details
Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

NCT01290549

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +17 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Stanford Cancer Institute Pharmacy Stanford, California, United States
  • Florida Cancer Specialists; Sarasota Sarasota, Florida, United States
  • Roswell Park Cancer Inst. Buffalo, New York, United States
View all 16 locations
View Trial Details
Completed

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

NCT01848145

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Florida Cancer Specialists-South Fort Myers, Florida, United States
  • Florida Cancer Specialists-North St. Petersburg, Florida, United States
  • Oncology Hematology Associates Cincinnati, Ohio, United States
View Trial Details

Related conditions